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OBJECTIVES We reviewed our institution’s experience with isolated (congenital) third-degree atrioventric-
ular block (CAVB) to identify pre- and post-natal predictors of mortality and the requirement
for pacemakers in infancy and childhood.
BACKGROUND Because of the relative rarity of the disease, there is a paucity of data concerning the outcome
of fetuses and children with isolated CAVB.
METHODS The medical records of all cases of CAVB encountered at our institution from January 1965
to December 1998 were analyzed.
RESULTS Of 102 cases identified, 29 were diagnosed in utero (F) at 26.1  5.6 weeks gestation, 33 as
neonates (N; 28 days), and 40 as children (C) at 5.7  4.8 years of age. Anti-Ro and/or
anti-La were present in 95% of F and 90% of N, but only in 5% of C mothers tested (p 
0.0001). Patients with CAVB having F, N and C diagnosis had a mortality of 43%, 6% and
0%, respectively, in the first two decades of life. Increased mortality risk was associated with
a fetal diagnosis of CAVB (13/15 deaths; p  0.05), fetal hydrops (6/6 cases; p  0.0001),
endocardial fibroelastosis (5/5 cases; p  0.0001) and delivery at 32 weeks (4/6 cases; p 
0.05). Timing of pacemaker implantation differed significantly among F versus N (p  0.05)
and N versus C (p  0.001) cases. At 20 years of age only 11% and 12% of CAVB patients
with N and C diagnosis, respectively, were not paced.
CONCLUSIONS Pre-natal diagnosis of CAVB is associated with high fetal and neonatal mortality. Among
survivors, whether the diagnosis is made before or after birth, most undergo pacemaker
implantation by adulthood, with earlier intervention and a significantly greater need for
reintervention among those diagnosed in utero. (J Am Coll Cardiol 2002;39:130–7)
© 2002 by the American College of Cardiology
Isolated congenital third-degree atrioventricular block
(CAVB) occurs in one in 14,000 to 20,000 live births (1)
and has been recognized as a distinct clinical entity for
almost 100 years (2). Neonatal lupus erythematosus ac-
counts for 90% to 99% of all cases identified before six
months and is associated with the transplacental passage of
maternal anti-Ro and/or anti-La autoantibodies (3–6).
These antibodies enter the fetal circulation beginning in the
mid-second trimester (7) and may lead to permanent de-
struction of the atrioventricular (AV) conduction system (8).
With the advent of fetal echocardiography, which allows
for accurate assessment of the fetal heart rate, rhythm and
ventricular function, the majority of autoimmune-mediated
CAVB may now be identified in utero before 30 weeks of
gestation (9). However, as many as 50% of the total cases of
isolated CAVB presenting during childhood are detected
after six months of age (10). It has been suggested that
children presenting late with CAVB may represent a dif-
ferent serological and clinical population, as maternal auto-
antibodies are frequently absent, the bradycardia is better
tolerated, and the children are less likely to need early
pacing (11).
The aim of our study was to outline the clinical presen-
tation, management and course of fetuses and children
diagnosed with CAVB at our institution. The second aim
was to identify clinical, electrocardiographic and echocar-
diographic parameters that may predict long-term outcome
and pacemaker requirement during infancy and childhood.
METHODS
We reviewed the diagnostic database of the Division of
Cardiology at The Hospital for Sick Children for the years
1965 to 1998 and identified all patients with a diagnosis of
CAVB. The diagnostic criteria of third-degree AV block
proposed by Yater et al. (12) were applied and modified for
this study. Isolated congenital third-degree atrioventricular
block was defined as complete if there was no electrical
(post-natal electrocardiogram) or mechanical (fetal
M-mode echocardiogram) relation between atrial and ven-
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tricular contraction, and incomplete if this relation was
present intermittently. The diagnosis of CAVB also re-
quired the absence of a history of any condition, including
infections, myopathies, metabolic disorders or significant
intracardiac structural malformation, that might result in or
be associated with CAVB after birth. The time of detection
of CAVB was taken as the earliest documentation of a
patient’s conduction abnormality, which usually occurred
near the time of referral to our center.
The medical records of the affected patients were re-
viewed. Data collected included demographic information,
patient age and status at presentation, pacemaker interven-
tion procedures and patient age and status at follow-up.
Data regarding signs and symptoms of maternal autoim-
mune disease, presence or absence of maternal autoimmune
antibodies, medications taken during the pregnancy, gesta-
tional length of pregnancy, mode of delivery and presence or
absence of malformations in the offspring were collected.
After informed consent had been given, maternal sera were
obtained, and anti-Ro and anti-La antibody status was
determined using our previously described enzyme linked
immunosorbent assay technique (13).
Videotaped recordings of fetal echocardiographic exami-
nations were reviewed to determine the underlying rhythm
and ventricular rates. Electrocardiographic tracings were
reanalyzed for rhythm, atrial and ventricular rates, degree of
AV block, QRS duration, and corrected QT (if QRS
0.1 s; normal: 0.45 s) or JT interval (if QRS 0.1 s;
normal: 0.32 s) using Bazett’s formula (14). Where
available, Holter monitor data were examined for minimal,
maximal and average ventricular rates, maximal duration of
pauses and the presence or absence of significant ventricular
arrhythmia. Our practice of pacemaker implantation was
compared to the American College of Cardiology/American
Heart Association (ACC/AHA) guidelines for pacemaker
implantation in children and adolescents (15).
Statistical analysis. Data were expressed as frequencies,
mean  standard deviation and median and range, as
appropriate. Differences in characteristics, management and
outcome over time were determined by creating three
patient groups depending on age of CAVB diagnosis: 1)
fetal (F); 2) neonatal (28 days, N); or 3) childhood (28
days to 18 years, C). Comparison of the three groups was
initially performed with the 2 test for categorical variables
and the Kruskal-Wallis nonparametric test for continuous
variables. If the overall test was found significant, further
comparison between the groups of interest was based on the
Fisher exact test for frequencies and the Mann-Whitney U
test for continuous variables. In order to account for
multiple comparisons a conservative Bonferroni penalty was
introduced by multiplying the p value by the number of tests
performed. Kaplan-Meier product limit estimates were used
to plot survival and freedom from pacemaker implantation.
Log-rank tests were used to compare survival and freedom
from pacemaker among the three groups. Further compar-
ison between two groups of interest was done with the
log-rank test and a Bonferroni correlation for the p value, as
described above. In order to estimate a relative risk of
pacemaker implantation between groups a Cox proportional
hazards model was applied using the childhood group as a
baseline. A p value 0.05 was considered statistically
significant.
RESULTS
Table 1 summarizes the clinical data of 102 cases of CAVB
identified at our institution from 1965 to 1998. Figure 1
Abbreviations and Acronyms
ACC/AHA  American College of Cardiology/
American Heart Association
AV  atrioventricular
CAVB  isolated congenital atrioventricular block
CI  confidence interval
CR  cumulative risk
EFE  endocardial fibroelastosis
HF  heart failure
Table 1. Characteristics of 102 Pre- and Post-Natally Diagnosed Cases With Isolated CAVB
Overall Fetal Cases Neonatal Cases Childhood Cases
2 p Value
Number
or Median
Range
or %
F vs. N
p Value
Number
or Median
Range
or %
Number
or Median
Range
or %
N vs. C
p Value
Case numbers 29 33 40
Seropositive/tested mothers 48.4 0.0001 21/22 95% NS 24/27 90% 1/20 5% 0.0001
Male/female 1.4 NS 14/11* 56% male 12/21 36% male 17/23 43% male
Lower grade AVB at diagnosis 6.6 0.04 1/22 4.5% NS 1/33 3% 9/40 23% NS
Pacemaker† 0.1 NS 11/16 69% 24/33 73% 28/40 70%
Age (yrs) at first pacemaker 31.7 0.0001 0.025 0.003–3.9 0.02 1.5y 0.005–25.3 10.2 0.23–18.7 0.001
Single/dual chamber pacer‡ 13.8 0.001 14/1 93% single NS 19/5 79% single 13/17 43% single 0.02
Mortality rate 29.8 0.0001 13/29 45% 0.002 2/33 6% 0/40 0% NS
Age (yrs) at last follow-up 37.5 0.0001 0.7 0–11.6 0.0001 9.9 0.8–27.7 14.2 1.1–27.1 0.02
*Gender unknown in four cases of intrauterine demise; †ratio of permanent pacemaker implantation in cases surviving the neonatal period; ‡ratio of patients with
single-chamber/dual-chamber pacing mode at first pacemaker implantation.
Data are presented as median and range, or percentage (%). Statistical comparisons were initially done among the three groups, and if the overall test was found significant,
further comparison using a Bonferroni penalty was made between cases with neonatal versus fetal and cases with neonatal versus childhood diagnosis of CAVB, respectively.
AVB  atrioventricular block; C  childhood; CAVB  congenital atrioventricular block; F  fetuses; N  neonatal period; NS  not significant.
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shows the number of patients among the fetal, neonatal and
childhood diagnosis groups identified during three different
time periods.
Fetal group. Twenty-nine cases of CAVB were detected
pre-natally, with the majority (19/29) diagnosed before 30
weeks of gestation (mean 26.1  5.6 weeks, median 26
weeks, range 18 to 37 weeks). The primary indications for
fetal echocardiography were for a diagnosis of fetal brady-
cardia (27/29) and hydrops fetalis (6/29). Anti-Ro antibo-
dies were found in 20/22 tested mothers (15 Ro/La, 3
Ro/La-, 2 Ro/La not tested), and anti-La antibodies
were found in isolation in one additional mother. Despite
the presence of positive serology in 95% of tested mothers,
only two had signs and symptoms of a connective tissue
disease at the time of fetal CAVB diagnosis. One mother
had a therapeutic abortion at 21 weeks for severe hydrops
fetalis and endocardial fibroelastosis (EFE). Eleven mothers
received dexamethasone, which was initiated at the time of
diagnosis of fetal CAVB, with (n  5) or without (n  6)
the presence of hydrops fetalis. In two mothers terbutaline
therapy was initiated for a fetal ventricular rate of 55
beats/min (one with a 15% increase, one without change).
Finally, one mother underwent fetal pericardiocentesis for a
large pericardial effusion. Spontaneous intrauterine fetal
death occurred in six cases: two with hydrops fetalis and
EFE; one with ventricular rate50 beats/min and two with
rates 55 beats/min, all three without hydrops fetalis; and
one after placental infarction. There were three intrauterine
deaths despite maternal dexamethasone (n  3) and ter-
butaline (n  1) therapy.
Twenty-two (76%) of the fetal cases with CAVB were
live-born at a mean gestational age of 35.1  3.5 weeks
(median 36 weeks, range 27 to 40 weeks). All had CAVB
confirmed at birth with junctional (n  21) or ventricular
(n  1) escape rhythms ranging from 40 to 90 beats/min
(mean 53.5  14.8). Transiently prolonged QTc intervals
(range 0.48 to 0.51 s) were measured in five patients with
junctional escape rhythms. One neonate had a prolonged
QT syndrome with a ventricular broad QRS (100 ms)
complex escape rhythm between 36 and 75 beats/min,
severely prolonged JTc interval (0.43 s) and multiple epi-
sodes of torsade de pointes. The majority (15/22; 68%) of
the neonates required some form of medical intervention
shortly after birth, which consisted of isuprel (n  9),
corticosteroids (n  3) and ventricular pacing (n  12),
including permanent epicardial pacing at 1,500 g. Six
neonates died within one week of birth. The cause of death
was related to at least one of the following: premature
delivery (32 weeks gestation) in four patients; hydrops
fetalis in three, EFE in one and long QT syndrome with
ventricular fibrillation in one. No further deaths occurred
after the neonatal period; however, one child with CAVB
required cardiac transplantation because of progressive di-
lated EFE cardiomyopathy at 3.5 years of age. To date, a
permanent pacemaker has been implanted in 11 of 16
infants who survived the neonatal period (69%).
Neonatal group. In 33 patients, although low heart rates
were detected perinatally, isolated CAVB was diagnosed
only after birth. As a consequence of late recognition of
CAVB as the cause of fetal bradycardia, 14 of the 33
neonatal diagnosis group cases were delivered by emergency
caesarian section between 28 and 42 weeks gestation for
suspected fetal distress. Mean age at delivery was at 39.2 
2.5 weeks of gestation (median 39.5 weeks, range 28 to 42
weeks). Anti-Ro antibodies were present in 24 of 27 (89%)
mothers tested (11 Ro/La, 7 Ro/La-, 6 Ro/La not
tested). Neonatal electrocardiograms, available for reanalysis
in 29 of 33 (88%) cases, showed permanent CAVB in all but
one newborn. This latter patient had episodes of residual
AV nodal conduction (first- to third-degree AV block). The
ventricular rates ranged from 30 to 80 beats/min, with mean
rates of 53.1  13.7 beats/min. The escape rhythm was
junctional in 26. One had additional atrial flutter and
underwent D/C cardioversion. Three cases had broad QRS
(90 to 140 ms) complex ventricular escape rhythms with left
(n  2) or right bundle branch block morphology, and one
had prolonged JTc interval of 0.44 s without symptoms.
Five neonates presented with signs of congestive heart
failure (HF), but none had hydrops fetalis. Nine (27%)
received isuprel (n  2), and/or pacemaker (n  8)
treatment as newborns. There were no neonatal deaths, but
two (6%) patients died at 0.9 and 1.5 years of age. One died
of low output failure after an episode of severe bradycardia.
The other developed poor ventricular function and EFE
over the first year of life and died of therapy-refractory
ventricular fibrillation during a diagnostic cardiac catheter-
ization procedure. At a mean follow-up of 9.9  6.4 years
(median 9.9, range 0.78 to 27.7 years), 24/33 (73%) had
required a permanent pacemaker.
Childhood group. Forty patients were first diagnosed with
CAVB in childhood at a mean age of 5.7  4.8 years
(median 4.8 years, range 0.1 to 18 years). Of 20 mothers
tested, only one was positive for anti-Ro antibodies (5%)
and none were positive for anti-La antibodies. Six of the 40
Figure 1. Number of new cases diagnosed with isolated complete heart
block during different time periods.
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patients presented with bradycardia-related symptoms (four
with syncope, two with reduced exercise tolerance) at
diagnosis. The CAVB was complete at first presentation in
31 cases, with ventricular rates ranging from 32 to 65
beats/min. The CAVB was intermittent but predominated
in eight patients, whereas one case had second-degree AV
block with 2:1 AV conduction at diagnosis. Six of these
latter nine patients progressed to complete CAVB during
childhood. Thirty-eight patients had narrow QRS (junc-
tional) and two patients had broad QRS (ventricular)
complex escape rhythms on electrocardiogram. The QTc
interval was normal in all but one. One five-year-old boy
with a history of convulsions and episodes of torsade de
pointes and ventricular tachycardia on 24-h Holter had a
QTc interval of 0.62 s. At a mean follow-up of 7.8  5.1
years (median 7.2, range 0.1 to 18.6 years) all patients with
a childhood diagnosis of CAVB were alive and well,
although 28 of 40 (70%) had undergone a permanent
pacemaker implantation.
Mortality. Overall, there were 15 deaths, 13 of which
occurred in patients diagnosed pre-natally. Kaplan-Meier
survival analysis (Fig. 2) showed comparable survival rates of
94% (95% confidence interval [CI]: 77 to 98) for the
neonatal and 100% for childhood cases (p NS) in the first
20 years after birth. By contrast, only 73% (95% CI: 49 to
87) of the live born fetuses with CAVB reached 10 years of
age (log-rank test p  0.001). The majority of these deaths
were in the neonatal period (F versus N: 6/22 versus 2/33,
2 p  0.05). Results of risk factor analyses of death are
shown in Table 2. Risk factors for death in addition to fetal
diagnosis included hydrops fetalis, EFE, delivery at 32
weeks of gestation and a post-natal ejection fraction by
echocardiography of 40%. Of note, of the four cases with
pre-term delivery at 32 weeks, three had gross hydrops
fetalis, which clearly contributed to their demise. Maternal
autoantibodies, fetal heart rate of 55 beats/min, the
presence of ventricular ectopy and the QRS duration were
not significant risk factors for death.
Pacemaker implantation. The timing of pacemaker im-
plantation differed significantly between the three groups
(log rank, 2  28.4, p  0.0001). By 20 years of age only
11% of neonatal and 12% of childhood cases had not
required pacemaker implantation. Kaplan-Meier estimates
of freedom from pacemaker implantation (Fig. 3) of the
fetal neonatal and childhood cases were 29% (95% CI: 12 to
51), 73% (95% CI: 54 to 85) and 98% (95% CI: 84 to 100)
at six months. At 10 years estimates were 22% (95% CI: 8
to 40) and 64% (95% CI: 46 to 77) for the neonatal and
childhood cases, respectively. Compared with the childhood
group (baseline risk), the relative risk of pacemaker implan-
tation was 6.2 (95% CI: 3 to 12.7) in the fetal group and 2.2
(95% CI: 1.2 to 3.8) in the neonatal group. The criteria for
pacemaker implantation among the three patient groups,
expressed in the standard ACC/AHA format (15), are listed
in Table 3. Although some patients fulfilled several criteria,
only one—the “most relevant” reason for pacemaker im-
plantation—is indicated for each patient. Class I criteria was
fulfilled in 14 of 15 fetal, 16 of 24 neonatal and 12 of 28
Figure 2. Kaplan-Meier survival of CAVB diagnosed during the fetal,
neonatal and childhood periods differed significantly between the groups
(log-rank; 2  17.2, p  0.0002). Further analyses using log-rank tests
with Bonferroni corrections confirmed the reduced survival rate of the fetal
cases (fetal vs. neonatal: 2  6.04, p  0.03; fetal vs. childhood: 2 
12.3, p  0.001).
Table 2. Risk Factor Analyses of Mortality of CAVB Diagnosed In Utero, in the Newborn Period or During Childhood
Patient Groups
Analyzed (n)
Death Among
Affected Cases
Death Among
Nonaffected Cases
p Value
(Risk for Death)
Maternal autoantibodies* AB(46) vs. AB(23) 6/46 0/23 NS
Fetal diagnosis‡ F(22) vs. NC(73) 6/22 2/73 0.02
Hydrops fetalis* F(29), N(33) 6/6 9/56 0.0001
Endocardial fibroelastosis* F(29), N(33), C(40) 5/5 10/82 0.0001
Fetal heart rate 55 beats/min* F(29) 9/14 4/15 NS
Delivery 32 weeks‡ F(22), N(33) 4/6† 4/49 0.03
Left ventricular ejection fraction 40% (echo)‡ F(13), N(26), C(36)§ 6/7 0/68 0.0001
VT/polymorphous PVC (Holter)‡ F(13), N(26), C(32) 1/6 1/65 NS
QRS duration 0.10 s (ECG)† F(22), N(30), C(39) 1/7 4/84 NS
*Fetal and post-natal mortality; †three with demise also had gross hydrops fetalis; ‡mortality of live-born fetal and neonatal cases; §includes only patients with echocardiogram(s)
after birth at The Hospital for Sick Children. In order to account for multiple comparison of the nine different risk factors a conservative Bonferroni penalty was introduced by
multiplying the p values by 10.
AB or AB  maternal autoantibody positive or negative cases; C  childhood diagnosis; CAVB  isolated congenital third-degree atrioventricular block; F  fetal
diagnosis; N  neonatal diagnosis, NS  not significant; PVC  premature ventricular complexes; VT  ventricular tachycardia.
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childhood cases. Of symptomatic patients, congestive HF at
birth was the main cause for early neonatal pacemaker
placement. By contrast, syncopal episodes were experienced
in three neonatal and 11 childhood cases at ages ranging
from 0.5 to 25 years. Most of the cases diagnosed during
childhood received a permanent pacemaker for class IIa
indications, including low mean ventricular heart rates
( 40 beats/min: four cases; 40 to 50 beats/min: eight
cases) and/or pauses of 3 s (four cases), before the
appearance of major symptoms. Analysis of Holter findings,
including average heart rate, minimal heart rate and the
presence of 3 s pauses, and exercise test results, including
maximum heart rate and endurance, revealed no significant
difference between patients undergoing pacemaker implan-
tation for syncope (Class I indications), Class II indications
(prophylactic pacing) and unpaced patients (Table 4).
Pacemaker treatment had some important limitations and
risks. Sixteen (25%; 3 F, 10 N, 3 C) of 63 patients who
required pacemakers experienced at least one complication
at the time of pacemaker implantation (three wound infec-
tions, one endocarditis, one cardiac perforation, one supe-
rior vena cava thrombosis) or within months of pacemaker
implantation (10 ventricular lead fractures/loss of ventricu-
lar capture). The most common reasons for repeat interven-
tions included pacemaker, lead and battery replacements,
especially in young patients. All fetal cases underwent an
average of 1.3 pacemaker interventions during a mean
follow-up period of 3.1  3 years after the first pacemaker
surgery (cumulative risk [CR] of 4.2 pacemaker interven-
tions/10 years). The neonatal cases required 2.2 interven-
tions during a mean follow-up period of 7.6  5.2 years
(CR: 2.9 interventions/10 years), and childhood cases re-
quired 1.2 interventions during a mean follow-up period of
5  3.2 years (CR: 2.4 interventions/10 years) after the first
pacemaker intervention. In addition, six of the eight pa-
tients who died after birth had undergone pacemaker
insertion before death.
DISCUSSION
Our retrospective study represents the largest reported
single institution’s experience with CAVB in fetuses, infants
and children. In our review of 102 cases of CAVB, we have
identified risk factors for mortality, which include a fetal
diagnosis, fetal hydrops, ventricular EFE and delivery at
32 weeks of gestation. We have also demonstrated a
significantly higher risk of early pacemaker insertion and
repeat pacemaker-related interventions among patients with
a pre-natal versus a post-natal diagnosis of CAVB. With
Figure 3. Kaplan-Meier freedom of pacemaker implantation comparing
fetal, neonatal and childhood diagnosis of CAVB. Global differences
between the groups (log-rank; 2 28.4, p 0.001) were further analyzed
using log-rank tests and Bonferroni corrections. Time of implantation
differed significantly between the childhood group and the neonatal group
(2  7.8, p  0.02) and between the childhood group and the fetal group
(2  33.9, p  0.001) but not between the neonatal and fetal groups
(2  4.4, p  0.09) after adjustment for multiple comparison.
Table 3. ACC/AHA Criteria for Permanent Pacing of 67 of 102 Patients With Diagnosis of
CAVB In Utero, as Newborn or During Childhood
Class Third-Degree AVB With/In:
Fetal
Cases
(n  15)
Neonatal
Cases
(n  24)
Childhood
Cases
(n  28)
I (1) Symptomatic bradycardia, congestive heart failure,
low output
6 9 10
I (4) Wide QRS escape rhythm or ventricular
dysfunction
0 1 0
I (5) Infant with a ventricular rate 50 to 55 beats/min 7 5 1
I (6) Sustained pause-dependent VT with and without
prolonged QT
1 1 1
IIa (2) CAVB beyond one year of age with a mean heart
rate 50 beats/min or abrupt pauses in VR that
are 2 to 3 times the basic cycle length
0 7 14
IIb (2) Asymptomatic neonate, child or adolescent with
an acceptable rate, narrow QRS complex and
normal ventricular function
1 1 0
Others No ACC/AHA criteria 0 0 2*
*One patient underwent pacemaker implantation for vasovagal syncope, one patient for poor heart rate response during exercise
test.
ACC/AHA  American College of Cardiology/American Heart Association; CAVB  isolated congenital third-degree
atrioventricular block; VR  ventricular rhythm; VT  ventricular tachycardia.
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advances in ultrasonographic technology and a growing
experience in pre-natal assessment, CAVB has become
reliably detectable in utero within the past two decades. The
widespread use of pre-natal ultrasound screening provides
explanation for the remarkable shift from neonatal towards
a pre-natal diagnosis experienced in the most recent years
(9).
Pre-natally diagnosed CAVB. As has been shown for
structural cardiovascular abnormalities, our study suggests
that CAVB detected in utero represents a more severe
spectrum of the disease than encountered post-natally.
Cases with hydrops fetalis, poor ventricular function and
EFE are more likely to be detected during pregnancy.
Although the pre-natal use of corticosteroids (16), plasma-
pheresis (17), sympathomimetics (18) and either pre-natal
pacing (19) or early delivery with post-natal pacing (20) has
been proposed, the true efficacy of therapy is not clear.
Overall, the mortality of our fetal series was 43%, despite
the frequent use of corticosteroids and inotropic agents pre-
(38%) and post-natally (73%), and immediate ventricular
pacing after delivery (55%). Furthermore, in contrast to a
recent retrospective multicenter study (16), corticosteroid
usage during pregnancy did not reverse hydrops fetalis or
reduce the severity of AV block. A prospective multicenter
study would clarify the real benefit of such a therapy, which
may be more in the prevention of autoimmune-mediated
pathology such as myocarditis and EFE.
Risk factor analysis indicated that the presence of hydrops
fetalis was associated with a poor outcome, with a combined
fetal and neonatal mortality of 100% in the present and 83%
to 100% in published series (21). The emergence of hydrops
fetalis in association with immune-mediated CAVB has
been attributed to attenuated cardiac output due to brady-
cardia and electromechanical AV dissociation as well as
myocarditis (17). In the present report, of the six cases with
hydrops, three had EFE with ventricular dysfunction. En-
docardial fibroelastosis has been previously described in the
presence of CAVB (22,23), and we and others have shown
deposition of maternal autoantibodies on the fetal myocar-
dium (24,25). Although EFE was present in only a minority
of our cases (5% overall, 14% of fetal cases), it accounted for
more than one-third of the deaths. To our knowledge, this
study is the first to demonstrate the incidence and important
clinical impact of EFE among “isolated” CAVB patients.
Previous pre-natal reports have suggested a worse out-
come for pre-natally diagnosed CAVB associated with
negative maternal anti-Ro antibody status (21), and for
fetuses (26) and neonates (27) with ventricular rates of 55
beats/min. In our series, all four patients with autoantibody-
negative mothers and a fetal or neonatal diagnosis survived.
However, 19% of those born to mothers with autoantibod-
ies died, suggesting a worse outcome for autoantibody-
associated CAVB. The majority of fetuses with ventricular
rates of 55 beats/min did not survive the perinatal period
in our experience, but this did not reach statistical signifi-
cance. It is possible that the “natural history” of some of
these fetuses had been altered by the use of pharmacological
agents and aggressive perinatal management, including
early, planned deliveries and immediate post-natal ventric-
ular pacing. In contrast to the fetal diagnosis group, the
outcome of CAVB detected after birth was excellent, with
no severe HF observed among affected neonates and only a
minority requiring therapy during the newborn period.
Based on our experience, our current approach to affected
pregnancies is to initiate dexamethasone therapy at diagno-
sis of fetal AV block (4 mg/day) and to use maternal
sympathomimetics for fetal ventricular rates of 55 beats/
min. Weekly-biweekly fetal echocardiograms are used to
follow the progress, and an elective delivery by caesarian
section at 36 to 37 weeks is planned. If there is evidence of
fetal compromise (e.g., pericardial effusion, ascites, increas-
ing ventricular ectopy, reduced ventricular shortening frac-
tion or AV valve regurgitation), we have elected for an
earlier delivery with aggressive post-natal management,
including placement of a permanent pacemaker as an early
step. When there is oligohydramnios, maternal dexameth-
asone is tapered off; however, persistence of reduced amni-
otic fluid may prompt earlier delivery.
Table 4. Analysis of Heart Rate on 12-Lead ECG, Holter and Exercise Test of Class 1 and Class 2 N and C Patients and
Unpaced Cases
Class
12-Lead ECG Holter ET
PM Age
at First
Age
(yrs) HR Number Age HR
Min
HR
Pauses
>3 s Number Age Max HR Endurance
Class 1 0.6 50.5 20/28 6.2 51 34 5/20 8/28 12.2 123 10.5 2.2
n  28 (no females) (0–17.5) (35–76) (71%) (0–25) (32–77) (18–59) (25%) (29%) (7.2–15.4) (68–164) (10–13) (0.01–25)
No syncope 0.02 54.5 9/15 0.5 50 43 2/9 2/15 10.9 109 10.5 4.6
n  15 (0–5.3) (35–76) (60%) (0–17) (35–77) (27–59) (22%) (13%) (8.9–12.9) (82–136) (10–11) (0.01–18)
Syncope 8.9 47.5 11/13 7.6 52 28 3/11 7/13 12.2 123 11 8.5
n  13 (0.5–17.5) (38–62) (85%) (0.5–25) (32–60) (18–38) (27%) (54%) (7.2–15.4) (68–164) (10–13) (0.5–25)
Class 2 3.8 50 19/21 6.4 47 24 11/19 7/21 11.6 118 10 7.9
n  21 (0.08–19.2) (32–80) (90%) (2–19) (37–80) (17–41) (58%) (33%) (10–19.2) (70–135) (7–12) (1.9–19)
No PM 7.1 52 21/25 4.2 57 39 2/18 11/25 12 128 10 N/A
n  25 (0.01–19.5) (36–80) (84%) (0.01–17.4) (43–79) (32–77) (11%) (44%) (5.5–17) (111–140) (7–12)
Values are shown as median and range or ratio and percentage.
C  childhood; ECG  electrocardiogram; Endurance  ET duration in minutes; ET  exercise test; HR  heart rate; Min HR  minimal heart rate on Holter; N 
neonatal period; PM  pacemaker.
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Pre-natal versus post-natal diagnosis of CAVB. Despite
the comparable outcome of CAVB diagnosed neonatally or
during childhood, our data continue to support the existence
of two distinct clinical and serological entities. Although
anti-Ro and/or anti-La antibodies are present in most
mothers of offspring with CAVB diagnosed in the perinatal
period, they are found in only a minority of those diagnosed
after the newborn period. It is of note, however, that
autoantibody screening was performed in only 50% of the
mothers of children diagnosed beyond the newborn period,
and as such it may not be fully representative of the positive
mothers. There is evidence that once maternal anti-Ro/
anti-La autoantibodies are present, they remain so lifelong
(28), although the titers of the autoantibodies may change
over time (29–31). Thus, the absence of maternal antibodies
among patients presenting in childhood with isolated
CAVB suggests a different pathogenic mechanism such as a
degenerative process, when compared to isolated fetal and
neonatal CAVB. It has been suggested that most CAVB
diagnosed for the first time beyond infancy is congenital in
origin and has escaped notice because of a higher ventricular
rate and absence of symptoms (32). However, this statement
was made in the early days of pre-natal ultrasound assess-
ment. We suspect the majority of cases with a childhood
diagnosis have preserved AV conduction at birth and
acquire progressive AV nodal disease thereafter. This is
supported by the fact that our numbers of referred child-
hood cases have been stable during the past two decades
despite the introduction of fetal echocardiography and the
wide availability of heart rate monitoring during pregnancy
and labor. In addition, we have found CAVB to be absent
or incompletely present in about 25% of affected children at
their first clinical presentation (mean age 5.7 years). Al-
though our data would suggest that CAVB diagnosed
beyond the neonatal period is infrequently associated with
maternal autoantibodies at presentation, we still recom-
mend antibody screening of all mothers of affected children
presenting with a significant conduction abnormality, par-
ticularly given the implications for future pregnancies and
long-term maternal health (33,34).
Pacemaker implantation. Indications for permanent pac-
ing in children with CAVB have evolved on the basis of
natural history data and progress in pacemaker technology.
Recent data indicate that pacemaker implantation may
improve long-term survival and prevent syncopal events
among asymptomatic patients with CAVB (35). Neverthe-
less, several criteria must be considered to justify prophy-
lactic pacing in an asymptomatic patient with CAVB: the
average heart rate, duration of pauses in the intrinsic rate,
prolongation of the QT interval, wide QRS escape rhythm
and impaired exercise tolerance (15,27). Our data confirm
previous reports that most patients with CAVB will un-
dergo pacemaker therapy by adulthood (10,18,36). How-
ever, there are striking differences in terms of patient age
and indications for permanent pacing among our fetal,
neonatal and childhood diagnosis groups. Most pre-natally
diagnosed cases required a permanent pacemaker in early
infancy, mainly because of congestive HF and/or mean
ventricular rates of55 beats/min. Nearly two-thirds of the
cases diagnosed after birth were asymptomatic at the time of
pacemaker implantation, and underwent pacemaker im-
plantation prophylactically later in life, fulfilling the ACC/
AHA criteria of ventricular rates 55 beats/min as infants
or 50 beats/min after one year of age.
Unfortunately, pacemaker therapy was associated with a
significant rate of complications, which may occur in up to
25% of cases. Lead fractures and lead insulation breaks,
which occurred with loss of ventricular capture in 15% of
the 67 paced patients in the present series, are complications
that should be addressed with improved technology. In
addition, most pediatric patients not only will receive their
first pacemaker during childhood but also will eventually
require further interventions for generator, lead and battery
replacements.
Conclusions. Pre-natally diagnosed CAVB is associated
with a high mortality. Risk factors for worse outcome
include the coexistence of fetal hydrops and EFE, and
delivery at 32 weeks gestation. Among survivors, most
require pacemaker implantation during infancy, childhood
or adolescence, with earlier intervention and a significantly
greater need for re-intervention among those diagnosed
before birth. Finally, although prophylactic pacing may
reduce mortality, the use of pacemaker therapy is associated
with significant morbidity, which includes pacemaker mal-
function and the need for repeat interventions.
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